Barinthus Biotherapeutics Plc Is A Clinical Stage Biopharmaceutical Company Based In The United Kingdomit Specializes In Developing Novel Immunotherapies Aimed At Guiding T Cells To Combat Autoimmunityinflammatory Diseasesinfectious Diseasesand Cancerthe Company Is Publicly Traded On The Nasdaq Under The Ticker Symbol Brns Formed In 2021 From The Merger Of Vaccitech Plc And Avidea Technologiesbarinthus Biotherapeutics Builds On A Strong Foundation In Immunotherapy Developmentthe Company Utilizes Advanced Platformsincluding Chimpanzee Adenovirus Oxfordchadoxand Modified Vaccinia Ankaramva To Induce Immune Responses Against Various Diseasesits Snap Synthetic Platforms Focus On Tolerance And Cancer Immunotherapybarinthus Targets Conditions Such As Hepatitis Bhpvprostate Cancerand Autoimmune Diseases With A Dedicated Team Of Over 100 Professionalsbarinthus Biotherapeutics Is Committed To Advancing Its Immunotherapy Pipelinethe Company Has Garnered Support From Notable Investors And Partnersenhancing Its Mission To Improve Patient Outcomes Through Innovative Treatments
No conferences found for this company.
| Company Name | Vaccitech Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
